Health Care System Information Sharing: A Step Toward Better Health Globally

Eldessouki, Randa; Smith, Marilyn Dix

doi:10.1016/j.vhri.2012.03.022

Cited by 28 publications

(20 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recommendations for the conduct and transparent reporting of economic evaluations: perspective, target population, subgroup analyses, time horizon, assumptions required, modeling, preferred outcome measures, sensitivity analysis parameters, sensitivity analysis ranges, and methods for conducting sensitivity analyses. These elements were selected from variables in the ISPOR database [18,23].…”

Section: Presentation Formats and Approaches: Details On How Tomentioning

confidence: 99%

“…Detailed guidance on how to conduct an economic evaluation was not extracted (e.g., analytic approaches and distributions to apply) and is not the focus of this systematic review. When available, guideline characteristics from the ISPOR database [18,23] were used, and were verified with source documents by one author. A second author verified disagreements.…”

Section: Presentation Formats and Approaches: Details On How Tomentioning

confidence: 99%

“…Extracting qualitative data from a wide variety of guideline documents requires judgment. However, this task was facilitated by the use of a pre-existing database of guideline characteristics [18,23].…”

Section: Strengths and Limitationsmentioning

confidence: 99%

See 2 more Smart Citations

What Guidance are Economists Given on How to Present Economic Evaluations for Policymakers? A Systematic Review

2015

View full text Add to dashboard Cite

Health economists have consistent presentation formats and common reporting elements that should be considered when developing user-friendly explanations for general audiences. These overlap with policymakers' informational needs but may not be sufficient for understanding by nontechnical audiences. Developing presentation formats and tools that incorporate viewpoints of both economists and noneconomists will allow for better application of the results of economic evaluations and enhance the transparency and legitimacy of decision-making processes that are informed by economic evaluations.

show abstract

Section: Presentation Formats and Approaches: Details On How Tomentioning

confidence: 99%

Section: Presentation Formats and Approaches: Details On How Tomentioning

confidence: 99%

See 1 more Smart Citation

What Guidance are Economists Given on How to Present Economic Evaluations for Policymakers? A Systematic Review

2015

View full text Add to dashboard Cite

show abstract

“…Since the original Panel on Cost-Effectiveness in Health and Medicine proposed the use of a reference case as a benchmark of quality and methodological rigor (1, 2), various guidelines for conducting economic analyses have been proposed (3, 4). Over the last two decades, many countries, particularly high-income ones, have developed their own reference cases to inform decision-making in their health care systems (5–8). In contrast, most low- and middle-income countries (LMICs) have not developed such guidelines, possibly due to their limited capacity to do so (9).…”

Section: Introductionmentioning

confidence: 99%

Adherence to the iDSI reference case among published cost-per-DALY averted studies

Emerson

Panzer

Cohen

et al. 2018

Preprint

View full text Add to dashboard Cite

29Background: The iDSI reference case, originally published in 2014, aims to improve the quality 30 and comparability of cost-effectiveness analyses (CEAs). This study assesses whether the 31 development of the guideline has improved the reporting and methodology for CEAs using 32 disability-adjusted life-years (DALYs). 33 Methods: We analyzed the Tufts Medical Center Global Health CEA Registry to identify cost-34 per-DALY averted studies published from 2011 to 2017. Among each of 11 principles in the 35iDSI reference case, we translated all reporting standards and methodological specifications into 36 quantifiable yes/no questions and awarded articles one point for each item satisfied. We then 37 separately calculated reporting and methods scores, measured as percent adherence (0%=no 38 adherence, 100%=full adherence). Using the year 2014 as the dissemination period, we 39 conducted a pre-post analysis. Additionally, we conducted an analysis stratified by the 11 40 principles and examined different scoring strategies and dissemination periods in sensitivity 41 analyses. 42Results: Articles averaged 74% adherence to reporting standards and 60% adherence to 43 methodological specifications. Adherence to reporting standards increased slightly over time 44 (72% pre-2014 vs. 75% post-2014, p<0.01), but methodological adherence did not significantly 45 improve (59% pre-2014 vs. 60% post-2014, p=0.53). Overall, reporting adherence scores 46 exceeded methodology adherence scores (74% vs. 60%, p<0.001). Articles seldom addressed 47 budget impact (9% reporting, 10% methodology) or equity (7% reporting, 7% methodology). 10/1/2018 3 48 Conclusions:The iDSI reference case has substantial potential to serve as a useful resource for 49 researchers and policy-makers in global health settings, but greater effort to promote adherence 50 and awareness is needed to achieve its potential. 10/1/2018 4 51 Background 52 Since the original Panel on Cost-Effectiveness in Health and Medicine proposed the use 53 of a reference case as a benchmark of quality and methodological rigor (1, 2), various guidelines 54 for conducting economic analyses have been proposed (3, 4). Over the last two decades, many 55 countries, particularly high-income ones, have developed their own reference cases to inform 56 decision-making in their health care systems (5-8). In contrast, most low-and middle-income 57 countries (LMICs) have not developed such guidelines, possibly due to their limited capacity to 58 do so (9).Case (10, 11) to convey the breadth of its intended applicability. The iDSI Reference Case fills a 65 major gap in global health economics, as it serves as the only resource of best practices for 66 economic evaluation for many LMICs looking for guidance on resource prioritization. To date, 67 however, no study has examined the extent to which economic evaluations adhere to the iDSI 68 guidelines. We aimed to evaluate whether the development of the iDSI reference case has 69 improved adherence to best practices for economic evaluations in glo...

show abstract

“…New interventions offer the prospect of improved quality-of-life for sufferers as well as the possibility of reducing the direct and indirect cost of care. Assessing the net impact of a new treatment can be complex, and it is commonplace in many jurisdictions to use cost-effectiveness models to assist decision-making in deciding whether proposed innovations in care provision offer good value for money 14,15 .…”

Section: Introductionmentioning

confidence: 99%

A systematic review of cost-effectiveness modeling of pharmaceutical therapies in neuropathic pain: variation in practice, key challenges, and recommendations for the future

Critchlow

Hirst

Akehurst

et al. 2016

Journal of Medical Economics

View full text Add to dashboard Cite

Objectives: Complexities in the neuropathic-pain care pathway make the condition difficult to manage and difficult to capture in cost-effectiveness models. The aim of this study is to understand, through a systematic review of previous cost-effectiveness studies, some of the key strengths and limitations in data and modeling practices in neuropathic pain. Thus, the aim is to guide future research and practice to improve resource allocation decisions and encourage continued investment to find novel and effective treatments for patients with neuropathic pain. Methods: The search strategy was designed to identify peer-reviewed cost-effectiveness evaluations of non-surgical, pharmaceutical therapies for neuropathic pain published since January 2000, accessing five key databases. All identified publications were reviewed and screened according to pre-defined eligibility criteria. Data extraction was designed to reflect key data challenges and approaches to modeling in neuropathic pain and based on published guidelines. Results: The search strategy identified 20 cost-effectiveness analyses meeting the inclusion criteria, of which 14 had original model structures. Cost-effectiveness modeling in neuropathic pain is established and increasing across multiple jurisdictions; however, amongst these studies, there is substantial variation in modeling approach, and there are common limitations. Capturing the effect of treatments upon health outcomes, particularly health-related quality-of-life, is challenging, and the health effects of multiple lines of ineffective treatment, common for patients with neuropathic pain, have not been consistently or robustly modeled. Conclusions: To improve future economic modeling in neuropathic pain, further research is suggested into the effect of multiple lines of treatment and treatment failure upon patient outcomes and subsequent treatment effectiveness; the impact of treatment-emergent adverse events upon patient outcomes; and consistent and appropriate pain measures to inform models. The authors further encourage transparent reporting of inputs used to inform cost-effectiveness models, with robust, comprehensive and clear uncertainty analysis and, where feasible, open-source modeling is encouraged. ARTICLE HISTORY

show abstract

Health Care System Information Sharing: A Step Toward Better Health Globally

Cited by 28 publications

References 3 publications

What Guidance are Economists Given on How to Present Economic Evaluations for Policymakers? A Systematic Review

What Guidance are Economists Given on How to Present Economic Evaluations for Policymakers? A Systematic Review

Adherence to the iDSI reference case among published cost-per-DALY averted studies

A systematic review of cost-effectiveness modeling of pharmaceutical therapies in neuropathic pain: variation in practice, key challenges, and recommendations for the future

Contact Info

Product

Resources

About